MarketScreener Homepage > Equities > Tokyo Stock Exchange > Astellas Pharma Inc. 4503 JP3942400007

Report

End-of-day quote Tokyo Stock Exchange - 01/15
1662	JPY		+0.45%

01/14

ACTINIUM PHARMACEUTICALS : and Astellas Announce Research Collaboration Focused on Novel -225 Based Targeted Radiotherapies

01/06

ASTELLAS PHARMA INC. : - FDA Accepts for Priority Review the New Drug Application for mirabegron for Oral Suspension and Supplemental New Drug Application for Myrbetriq Tablets in Pediatric Patients

2020

ASTELLAS PHARMA : FDA Lifts Clinical Hold for Audentes Therapeutics' AT132 Trial

News

Most relevant

Official Publications

Sector news

Most relevant news about ASTELLAS PHARMA INC.

2020	ASTELLAS PHARMA : and Seattle Genetics Receive FDA Breakthrough Therapy Designat..	PU
2020	ASTELLAS PHARMA : XTANDI Demonstrates Significant Improvement in Overall Surviva..	AQ
2020	SEATTLE GENETICS : and Astellas Announce Updated Results from Phase 1b/2 Trial o..	AQ
2020	ASTELLAS PHARMA : Announces Management Structure	AQ
2020	ASTELLAS PHARMA : Announces Completion of Acquisition of Own Shares, and Cancell..	PU
2020	ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Evre..	AQ
2020	Astellas Pharma keeps profit forecast as prostate cancer drug sales rise	RE
2020	ASTELLAS PHARMA : Will Renew Its Corporate Website's Innovation Section	PU
2020	ASTELLAS PHARMA INC. : quaterly earnings release
2020	ASTELLAS PHARMA : Amgen astellas biopharma to become a wholly owned amgen affili..	PU
2020	ASTELLAS PHARMA : Announces Construction of New Manufacturing Facility for Activ..	AQ
2020	Amgen CEO expects 25% of growth to come from Asia in next decade	RE
2020	ASTELLAS PHARMA INC. : - U.S. FDA Approves Supplemental New Drug Application for..	AQ
2020	ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares	PU
2019	ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..	AQ
2019	Astellas ramps up M&A, buys U.S. biotech Xyphos for as much as $665 million	RE
2019	ASTELLAS PHARMA : Strengthens Immuno-oncology Pipeline with Acquisition of Xypho..	PU
2019	Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..	RE
2019	Roche dives deeper into gene therapy with $1.15 billion Sarepta licensing dea..	RE
2019	ASTELLAS PHARMA INC. : - FDA Grants Accelerated Approval to Astellas and Seattle..	AQ
2019	PFIZER INC. : - XTANDI Approved by U.S. FDA for the Treatment of Metastatic Cast..	AQ
2019	ASTELLAS PHARMA : Announces Key Leadership Promotions in Human Resources, Legal	AQ
2019	Nikkei bounces back on trade deal hopes, steelmakers shine	RE
2019	Japanese shares slip on concerns of longer trade war	RE
2019	Wall Street falls as trade hopes wane	RE
2019	ASTELLAS PHARMA : Presents New Data on XOSPATA in FLT3 Mutation-Positive Relapse..	AQ
2019	Seattle Genetics and Astellas Announce Clinical Trial Collaboration with Merc..	AQ
2019	Japan's Astellas to buy Audentes for $3 billion in high-priced gene therapy b..	RE
2019	Nikkei slips on fresh global trade concerns, weak U.S. data	RE
2019	ASTELLAS PHARMA : to buy U.S. biotech firm for $3 bil. to boost gene therapy	AQ
2019	ASTELLAS PHARMA : ACQUISITION OF AUDENTES - Establishing a leading position in g..	PU
2019	ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares	PU
2019	ASTELLAS PHARMA : Announces the Approval of XTANDI by the China National Medical..	AQ
2019	ASTELLAS PHARMA : and Welldoc Enter into Strategic Alliance for Digital Therapeu..	AQ
2019	ASTELLAS PHARMA : and Welldoc Enter into Strategic Alliance for Digital Therapeu..	PU
2019	ASTELLAS PHARMA : Announces Acquisition of Own Shares and Cancellation of Treasu..	PU
2019	ASTELLAS PHARMA : New England Journal of Medicine Publishes Results from Astella..	PU
2019	ASTELLAS PHARMA : Pandion and Astellas Announce Collaboration to Deliver Pancrea..	BU
2019	ASTELLAS PHARMA : U.S. FDA Grants Fast Track Designation to Astellas for the Dev..	PU
2019	Two charities to pay $6 million to resolve U.S. pharma kickback probe	RE
2019	ASTELLAS PHARMA : European Commission Approves Astellas' XOSPATA™ (gilteri..	PU
2019	ASTELLAS PHARMA : Announces Personnel Changes	PU
2019	ASTELLAS PHARMA : Transfers Three Products in Asia Region to Daiichi Sankyo	PU
2019	ASTELLAS PHARMA : Commits Nearly $13 Million to Fund Boston-area Start-Up Innova..	PU
2019	ASTELLAS PHARMA : Seattle Genetics and Astellas Announce Results from Phase 1 Tr..	PU
2019	ASTELLAS PHARMA INC : Ex-dividend day for interim dividend	FA
2019	ASTELLAS PHARMA : Receives Positive CHMP Opinion for XOSPATA® (gilteritinib) as ..	PU
2019	ASTELLAS PHARMA : Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatm..	PU
2019	ASTELLAS PHARMA : Seattle Genetics and Astellas Announce US FDA Grants Priority ..	PU
2019	ASTELLAS PHARMA : and iota Biosciences Enter into Collaborative Research and Dev..	PU
2019	ASTELLAS PHARMA : RIKEN and Astellas Enter into Worldwide Exclusive Licensing Ag..	PU
2019	ASTELLAS PHARMA : Yokohama City University, Tokyo University of the Arts and Ast..	PU
2019	ASTELLAS PHARMA : Submits Supplemental New Drug Application for Approval of Addi..	PU
2019	ASTELLAS PHARMA : Announces Acceptance by the European Medicines Agency of a Var..	PU
2019	ASTELLAS PHARMA : and Seattle Genetics Announce Submission of Biologics License ..	PU
2019	ASTELLAS PHARMA : Launch of Smyraf® Tablets - Provides a new therapeutic option ..	PU
2019	ASTELLAS PHARMA : Named to FTSE4Good Index Series for the Eighth Consecutive Yea..	PU
2019	ASTELLAS PHARMA : Hypercholesterolemia drug repatha® sc injection receives suppl..	PU
2019	ASTELLAS PHARMA : and Seattle Genetics Announce Antibody-Drug Conjugate Enfortum..	PU
2019	Drugmakers Astellas, Amgen to pay $125 million in U.S. charity kickback probe	RE
2019	ASTELLAS PHARMA INC : Ex-dividend day for final dividend	FA
2019	Cash-hoarding Japanese firms please investors as share buybacks hit record	RE
2018	ASTELLAS PHARMA : gets U.S. nod for blood cancer treatment	RE
2018	BIG PHARMA LEAVES BIG GAPS : drugmakers urged to do more for poor	RE
2018	ASTELLAS PHARMA INC : Ex-dividend day for interim dividend	FA
2018	ASTELLAS PHARMA : Receives Positive CHMP Opinion for XTANDI™ (enzalutamide..	PU
2018	ASTELLAS PHARMA : BLINCYTO® FOR DRIP INFUSION 35 μg APPROVED IN JAPAN FOR THE..	PU
2018	ASTELLAS PHARMA : Announces Approval in Japan for XOSPATA® 40 mg Tablets for the..	PU
2018	ASTELLAS PHARMA : Notice of Completion of Acquisition of Own Shares	PU
2018	ASTELLAS PHARMA : Announces Positive Topline Results for Global Phase 3 Trial of..	PU
2018	ASTELLAS PHARMA : Announces Launch of Dafclir® Tablets for the Treatment of Infe..	PU
2018	ASTELLAS PHARMA : Gene Therapy Research Institution and Astellas Executes Option..	PU
2018	ASTELLAS PHARMA : Announces Status of Acquisition of Own Shares	PU
2018	ASTELLAS PHARMA : Pfizer and Astellas Amend Clinical Research Protocols for Two ..	PU
2018	Pfizer, Astellas revise two cancer drug trial protocols to speed up results	RE

Prev.1 2 3 4 5 6 7 8 Next

Official Publications

2020	Half-year results
2020	4th quarter results
2020	Annual results
2020	Press Release
2020	3rd quarter results
2020	Press Release

More Official Publications

Upcoming event on ASTELLAS PHARMA INC.

01/29/21

Q3 2020 Präsentation des Ergebnisses

Company calendar

Upcoming sector events

01/26/21	JOHNSON & JOHNSON : FY 2020 Earnings Release
01/26/21	NOVARTIS AG : FY 2020 Earnings Release
01/28/21	LUPIN LIMITED : Q3 2021 Earnings Release
01/28/21	SUMITOMO DAINIPPON PHARMA CO., LTD. : Q3 2020 Earnings Release

More events

Sector

Healthcare
	Pharmaceuticals & Medical Research
		Pharmaceuticals
			Pharmaceuticals
				Pharmaceuticals - NEC